Loading...

Murali Ramachandran

Title(s)Member, CTSI
SchoolCTSI
Phone(310) 248-7681
vCardDownload vCard
    Other Positions
    Title(s)Director, CSMC Molecular Therapeutics Core

    Title(s)Immunology Research Research Scientist Biomedical Imaging Research Institute, Cedar-Sinai Medical Center


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 Aug; 18(8):1341-1354. PMID: 31142661.
      View in: PubMed
    2. Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018 12; 24(12):1887-1898. PMID: 30478421.
      View in: PubMed
    3. Wu R, Murali R, Kabe Y, French SW, Chiang YM, Liu S, Sher L, Wang CC, Louie S, Tsukamoto H. Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology. 2018 11; 68(5):1726-1740. PMID: 29729190.
      View in: PubMed
    4. Edderkaoui M, Chheda C, Soufi B, Zayou F, Hu RW, Ramanujan VK, Pan X, Boros LG, Tajbakhsh J, Madhav A, Bhowmick NA, Wang Q, Lewis M, Tuli R, Habtezion A, Murali R, Pandol SJ. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Gastroenterology. 2018 12; 155(6):1985-1998.e5. PMID: 30144430.
      View in: PubMed
    5. Chen CR, McLachlan SM, Hubbard PA, McNally R, Murali R, Rapoport B. Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity. Thyroid. 2018 07; 28(7):933-940. PMID: 29845889.
      View in: PubMed
    6. Kaplan A, Lee MW, Wolf AJ, Limon JJ, Becker CA, Ding M, Murali R, Lee EY, Liu GY, Wong GCL, Underhill DM. Direct Antimicrobial Activity of IFN-ß. J Immunol. 2017 05 15; 198(10):4036-4045. PMID: 28411186.
      View in: PubMed
    7. Lai KKY, Kweon SM, Chi F, Hwang E, Kabe Y, Higashiyama R, Qin L, Yan R, Wu RP, Lai K, Fujii N, French S, Xu J, Wang JY, Murali R, Mishra L, Lee JS, Ntambi JM, Tsukamoto H. Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6. Gastroenterology. 2017 05; 152(6):1477-1491. PMID: 28143772.
      View in: PubMed
    8. Ding H, Gangalum PR, Galstyan A, Fox I, Patil R, Hubbard P, Murali R, Ljubimova JY, Holler E. HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug. Nanomedicine. 2017 02; 13(2):631-639. PMID: 27520726.
      View in: PubMed
    9. Kanzaki H, Mukhopadhya NK, Cui X, Ramanujan VK, Murali R. Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-?B-Activation. Monoclon Antib Immunodiagn Immunother. 2016 Feb; 35(1):1-11. PMID: 26871511.
      View in: PubMed
    10. Kolar SL, Kyme P, Tseng CW, Soliman A, Kaplan A, Liang J, Nizet V, Jiang D, Murali R, Arditi M, Underhill DM, Liu GY. Group B Streptococcus Evades Host Immunity by Degrading Hyaluronan. Cell Host Microbe. 2015 Dec 09; 18(6):694-704. PMID: 26651945.
      View in: PubMed
    11. Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer. 2015 Dec; 15(6):448-457.e2. PMID: 26248960.
      View in: PubMed
    12. Xue J, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol SJ, Habtezion A. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nat Commun. 2015 May 18; 6:7158. PMID: 25981357.
      View in: PubMed
    13. Chen CR, Hubbard PA, Salazar LM, McLachlan SM, Murali R, Rapoport B. Crystal structure of a TSH receptor monoclonal antibody: insight into Graves' disease pathogenesis. Mol Endocrinol. 2015 Jan; 29(1):99-107. PMID: 25419797.
      View in: PubMed
    14. Hubbard PA, Moody CL, Murali R. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol. 2014; 5:478. PMID: 25566081.
      View in: PubMed
    15. Ohtaki A, Kieber-Emmons T, Murali R. Structure-based peptide mimicry of tumor-associated antigens. Monoclon Antib Immunodiagn Immunother. 2013 Feb; 32(1):1-5. PMID: 23600498.
      View in: PubMed
    16. Suhane S, Kanzaki H, Arumugaswami V, Murali R, Ramanujan VK. Mitochondrial NDUFS3 regulates the ROS-mediated onset of metabolic switch in transformed cells. Biol Open. 2013 Mar 15; 2(3):295-305. PMID: 23519235.
      View in: PubMed
    17. Kanzaki H, Ohtaki A, Merchant FK, Greene MI, Murali R. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. Exp Mol Pathol. 2013 Apr; 94(2):372-9. PMID: 23219833.
      View in: PubMed
    18. Hamidi S, Chen CR, Murali R, McLachlan SM, Rapoport B. Probing structural variability at the N terminus of the TSH receptor with a murine monoclonal antibody that distinguishes between two receptor conformational forms. Endocrinology. 2013 Jan; 154(1):562-71. PMID: 23183178.
      View in: PubMed
    19. Murali R, Greene MI. Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel). 2012 Feb 16; 5(2):209-35. PMID: 24288089.
      View in: PubMed
    20. Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, Tykocinski ML. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol. 2009 Feb; 174(2):460-74. PMID: 19147815.
      View in: PubMed
    21. Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 2005 Jun; 24(6):350-8. PMID: 15941387.
      View in: PubMed
    22. Horie T, Shen Y, Kajino K, Gaubin M, Bonomi G, Mani JC, Berezov A, Piatier-Tonneau D, Guardiola J, Hillard B, Rostami A, Greene M, Murali R. Study of disabling T-cell activation and inhibiting T-cell-mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidomimetics. Exp Mol Pathol. 2002 Oct; 73(2):93-103. PMID: 12231211.
      View in: PubMed